Biosimilars Market

R&D

Pioneering access to biosimilars is crucial for strengthening health equity by providing affordable, life-changing therapies to patients worldwide.

Partner Content

Biosimilars Market will surpass USD 69 billion by 2025

News

Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.